South Carolina is currently home to 1231 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
STEM-Parkinson's Disease
NCT04797611
Recruiting
This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/04/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Parkinson Disease, Parkinson's Disease and Parkinsonism
Register for Updates
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT04708782
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/04/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
NCT04464980
Recruiting
This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely disc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Shoreline Behavioral Health Services, Conway, South Carolina
Conditions: Opioid Use Disorder (OUD)
Register for Updates
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973
Recruiting
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Medical University of Southern Carolina, Charleston, South Carolina
Conditions: Metastatic Urothelial Cancer
Register for Updates
Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT03245489
Recruiting
The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Head and Neck Cancer
Register for Updates
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
NCT03173950
Recruiting
Background: More than 130 primary tumors of the central nervous system (CNS) have been identified. Most affect less than 1,000 people in the United States each year. Because these tumors are so rare, there are few proven therapies. This study will test whether the immunotherapy drug nivolumab is an effective treatment for people with rare CNS tumors. Objectives: To learn if stimulating the immune system using the drug nivolumab can shrink tumors in people with rare CNS (brain or spine) tumors... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/04/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Medulloblastoma, Ependymoma, Choroid Plexus Tumors, Atypical/Malignant Meningioma, Pineal Region Tumors
Register for Updates
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
NCT06254612
Recruiting
This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/03/2024
Locations: Coastal Carolina Research Center, North Charleston, South Carolina
Conditions: Major Depressive Disorder
Register for Updates
Induction in the Dark
NCT06144177
Recruiting
This study will enroll children ages 2-6 who are undergoing an elective outpatient surgical procedure under general anesthesia. They will be randomized to one of the following groups and assessed for preoperative anxiety, mask acceptance, and behavioral changes in the following week. darkened room and star projector with parental presence; preoperative midazolam 0.5 mg/kg by mouth and parental presence; or parental presence alone.
Gender:
All
Ages:
Between 2 years and 6 years
Trial Updated:
06/03/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Anesthesia Induction
Register for Updates
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
NCT06109649
Recruiting
The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.
Gender:
All
Ages:
12 years and above
Trial Updated:
06/03/2024
Locations: CLINUVEL Site, Charleston, South Carolina
Conditions: Vitiligo
Register for Updates
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
NCT06040086
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment. Participants should be receiving optimised treatment with inhaled maintenance therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) throughout at least the last 3 months prior to enrolmen... Read More
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
06/03/2024
Locations: Research Site, Gaffney, South Carolina
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
Amulet™ ADVANCE LAA
NCT05997446
Recruiting
This is a prospective, multicenter, observational study intended to characterize real-world outcomes on the commercially available Amulet device in the United States. The study will enroll approximately 1000 subjects at up to 50 US clinical sites. Subjects will be followed through 24 months in accordance with each site's standard care practices.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Roper Hospital, Charleston, South Carolina
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487
Recruiting
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: Randomized Arm - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients. Treatment Arm (Cohort 1) Active Control Arm (Cohort 2) Crossover Arm (Cohort 3) Single Arm - To demonstrate safety an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: PRISMA Health- Upstate, Greenville, South Carolina
Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III
Register for Updates